2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Kopel H, Nguyen V, Boileau C, Bogdanov A, Winer I, Ducruet T, Zeng N, Bonafede M, Esposito D, Martin D, Rosen A, Van de Velde N, Vermund S, Gravenstein S, Mansi J. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines 2023, 11: 1711. PMID: 38006043, PMCID: PMC10675676, DOI: 10.3390/vaccines11111711.Peer-Reviewed Original ResearchCOVID-19-related hospitalizationRelative vaccine effectivenessOutpatient visitsPrimary care electronic health recordsCOVID-19-related outcomesVaccine-induced protectionMedical claims dataCOVID-19 vaccineSARS-CoV-2Electronic health recordsVaccine effectivenessVaccine recipientsMRNA vaccinesBivalent vaccineBaseline differencesStudy populationClaims dataOmicron variantComparative effectivenessHospitalizationPropensity scoreVaccineOlder adultsHealth recordsVisits
2022
Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis
Deng L, Li P, Zhang X, Jiang Q, Turner D, Zhou C, Gao Y, Qian F, Zhang C, Lu H, Zou H, Vermund S, Qian H. Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. Scientific Reports 2022, 12: 20763. PMID: 36456577, PMCID: PMC9714387, DOI: 10.1038/s41598-022-24220-7.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 reinfectionSystematic reviewReinfection incidenceHazard ratioCase reportIncidence ratePrior SARS-CoV-2 infectionSARS-CoV-2 infectionIncidence of reinfectionInfection-naïve individualsRisk of reinfectionSARS-CoV-2 variantsRandom-effects modelSARS-CoV-2Web of ScienceCohort studyReinfection riskReinfection casesPrior infectionLower riskNew infectionsOmicron variantReinfectionInfection incidenceIncidenceNeutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine